A green and black tea extract benefits urological health in men with lower urinary tract symptoms

Therapeutic Advances in Urology

Volumn 6, Issue 3, 2014, Pages 89-96

  Katz, Aaron ^a   Efros, Mitchell ^a   Kaminetsky, Jed ^b   Herrlinger, Kelli ^c   Chirouzes, Diana ^c   Ceddia, Michael ^c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Kemin Industries Inc   (United States)

Author keywords

black tea; clinical trial; green tea; lower urinary tract symptoms; Men's Health

Indexed keywords

ASSURITEA MEN HEALTH; BLACK TEA EXTRACT; C REACTIVE PROTEIN; GREEN TEA EXTRACT; GREEN TEA EXTRACT PLUS BLACK TEA EXTRACT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AMERICAN UROLOGIC ASSOCIATION SYMPTOM SCORE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION; MULTICENTER STUDY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; TEA; TREATMENT DURATION; UROFLOWMETRY;

EID: 84899667548     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287214526924     Document Type: Article

References (19)

1. Barry M. Fowler F. Jr O–Leary M. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549–1557
2. Bent S. Kane C. Shinohara K. Neuhaus J. Hudes E. Goldberg H. (2006) Saw palmetto for benign prostatic hyperplasia. N Eng J Med 354: 557–566.
3. Bettuzzi S. Brausi M. Rizzi F. Castagnetti G. Peracchia G. Corti A. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234–1240.
4. Bogdanski P. Suliburska J. Szulinska M. Stepien M. Pupek-Musialik D. Jablecka A. (2012) Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res 32: 421–427.
5. Dvorkin L. Song K. (2002) Herbs for benign prostatic hyperplasia. Ann Pharmacother 36: 1443–1452.
6. Flannery M. Ramsdell J. Ranhosky A. Davidai G. Ruoff G. (2006) Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. Curr Med Res Opin 22: 721–730.
7. Hong H. Kim C. Maeng S. (2009) Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Practice 3: 323–327.
8. Hsu A. Bray T. Ho E (2010) Anti-inflammatory activity of soy and tea in prostate cancer prevention. Exp Biol Med (Maywood) 235: 659–667.
9. Jones C. Hill J. Chapple C. (2010) Guideline Development Group. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ 340: c2354.
10. Kim H. Park J. Cho Y. Cho C. Kim J. Shin H. (2013) Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta 832: 183–194.
11. Liao C. Chung S. Kuo H. (2011) Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology 78: 1373–1378.
12. McVary K. (2006) BPH: epidemiology and comorbidities. Am J Manag Care (5 Suppl.): S122–S128.
13. McVary K. Roehrborn C. Avins A. Barry M. Bruskewitz R. Donnell R. (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185: 1793–1803.
14. Sarma D. Barrett M. Chavez M. Gardiner P. Ko R. Mahady G. (2008) Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 31: 469–484.
15. Stull A. Cash K. Johnson W. Champagne C. Cefalu W. (2010) Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. J Nutr 140: 1764–1768.
16. Tab Schenk J. Kristal A. Neuhouser M. Tangen C. White E. Lin D. (2010) Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 171: 571–582.
17. Tacklind J. MacDonald R. Rutks I. Stanke J. Wilt T. (2009) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (2): CD001423.
18. Wei J. Calhoun E. Jacobsen S. (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173: 1256–1251.
19. Willetts K. Clements M. Champion S. Ehsman S. Eden J. (2003) Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 92: 267–270.